Cargando…
Prospective Comparative Study of Etoposide plus G-CSF versus G-CSF Alone, Followed by Risk-Adapted Plerixafor for Peripheral Blood Stem Cell Mobilization in Patients with Newly Diagnosed Multiple Myeloma: CAtholic REsearch Network for Multiple Myeloma Study (CAREMM-2001)
SIMPLE SUMMARY: We conducted a prospective trial comparing single-dose etoposide (375 mg/m(2) for one day) plus G-CSF versus G-CSF alone, followed by risk-adapted plerixafor in myeloma patients. Despite significantly less frequent (p = 0.045) use of plerixafor in the etoposide group, the optimal col...
Autores principales: | Park, Sung-Soo, Shin, Seung-Hwan, Lee, Jung-Yeon, Jeon, Young-Woo, Yhang, Seung-Ah, Min, Chang-Ki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10572075/ https://www.ncbi.nlm.nih.gov/pubmed/37835477 http://dx.doi.org/10.3390/cancers15194783 |
Ejemplares similares
-
High Efficacy of Stem Cell Mobilization With Etoposide+Cytarabine Plus G-CSF in Patients With Multiple Myeloma
por: Zhu, Zhijuan, et al.
Publicado: (2022) -
Plerixafor on-demand in association with low-dose cyclophosphamide and G-CSF in the mobilization of patients with multiple myeloma: High effectiveness, low toxicity, and affordable cost
por: Milone, Giuseppe, et al.
Publicado: (2020) -
A randomized phase II study of stem cell mobilization with cyclophosphamide+G-CSF or G-CSF alone after lenalidomide-based induction in multiple myeloma
por: Silvennoinen, R, et al.
Publicado: (2016) -
Multiple myeloma with G‐CSF production mimicking chronic neutrophilic leukemia
por: Ureshino, Hiroshi, et al.
Publicado: (2021) -
Stem Cell Mobilization with Ixazomib and G-CSF in Patients with Multiple Myeloma
por: Bühler, Selina, et al.
Publicado: (2023)